Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Recent Videos
Related Content
Data from Phase 2b of Opthea Limited wet AMD trial published

Data from Phase 2b of Opthea Limited wet AMD trial published

Grace Koennecke
March 5th 2025
Article
Adverum Biotechnologies initiates phase 3 ARTEMIS trial evaluating ixoberogene soroparvovec (Ixo-vec) in patients with wet AMD

Adverum Biotechnologies initiates phase 3 ARTEMIS trial evaluating ixoberogene soroparvovec (Ixo-vec) in patients with wet AMD

Martin David Harp
March 4th 2025
Article
Outlook Therapeutics resubmits BLA for ONS-5010 for treatment of wet AMD

Outlook Therapeutics resubmits BLA for ONS-5010 for treatment of wet AMD

Martin David Harp
March 2nd 2025
Article
FDA grants RMAT designation to RPESC-RPE-4W transplantation for AMD

FDA grants RMAT designation to RPESC-RPE-4W transplantation for AMD

Sydney M Crago
February 27th 2025
Article
Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06

Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06

Martin David Harp
February 21st 2025
Article
Opthea Limited completes week 52 patient visits in the COAST trial

Opthea Limited completes week 52 patient visits in the COAST trial

Sydney M Crago
February 20th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.